SCHEDULE 13G/A: American Endowment Foundation Amends Stake in Cyclerion Therapeutics, Reports 4.91% Ownership
Beneficial Ownership Report
American Endowment Foundation has filed an Amendment No. 2 to Schedule 13G, disclosing a 4.91% beneficial ownership stake in Cyclerion Therapeutics Inc. as of December 31, 2024.
Summary
- American Endowment Foundation filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Cyclerion Therapeutics Inc.
- As of December 31, 2024, American Endowment Foundation beneficially owned 133,026 shares of Cyclerion Therapeutics Inc. Common Stock.
- This ownership represents 4.91% of the outstanding Common Stock of Cyclerion Therapeutics Inc.
- The foundation holds shared voting power and shared dispositive power over all 133,026 shares.
- The filing was made under Rule 13d-1(b), indicating the reporting person is an institutional investor, specifically an endowment fund.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects.
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. Such filings provide transparency regarding significant ownership stakes, which can influence market perception and corporate governance discussions within the pharmaceutical and biotech sectors.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, which can offer insights into investor confidence or potential influence on corporate decisions.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event requiring the filing of this statement, reflecting the beneficial ownership position. |
| 02/12/2025 | Date the Schedule 13G Amendment No. 2 was signed by American Endowment Foundation. |
Keywords
Cyclerion Therapeutics Inc., American Endowment Foundation, Schedule 13G, Beneficial Ownership, Common Stock, CYCN, SEC Filing, Institutional Investor, Endowment Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.